Medicine Service, Birmingham VA Medical Center and Department of Medicine, University of Alabama, Birmingham, AL 35294, USA.
Arthritis Res Ther. 2010;12(5):136. doi: 10.1186/ar3110. Epub 2010 Sep 24.
In a previous issue of the journal, Becker and colleagues present efficacy and safety data from a large study comparing febuxostat to allopurinol. The study showed non-inferiority of febuxostat 40 mg/day in lowering serum urate compared to allopurinol 200 to 300 mg/day. More importantly, the study showed a similar frequency of important cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) for febuxostat 40 mg/day (0%), febuxostat 80 mg/day (0.4%) and allopurinol groups (0.4%). Other cardiac adverse event rates (unstable angina, coronary revascularization, cerebral revascularization, transient ischemic attack, venous and peripheral arterial vascular thrombotic event, congestive heart failure, and arrhythmia) were also similar for febuxostat 40 mg/day (1.3%), febuxostat 80 mg/day (1.2%) and allopurinol groups (0.9%). A meta-analysis of safety data from published studies is presented.
在该杂志的前一期中，Becker 及其同事报告了一项大型研究的疗效和安全性数据，该研究比较了非布司他与别嘌醇。该研究表明，与每天 200-300 毫克别嘌醇相比，每天 40 毫克非布司他降低血清尿酸的非劣效性。更重要的是，该研究显示，每天 40 毫克非布司他（0%）、每天 80 毫克非布司他（0.4%）和别嘌醇组（0.4%）的重要心血管不良事件（心血管死亡、非致死性心肌梗死和非致死性卒中）发生频率相似。其他心脏不良事件发生率（不稳定型心绞痛、冠状动脉血运重建、脑血运重建、短暂性脑缺血发作、静脉和外周动脉血管血栓形成事件、充血性心力衰竭和心律失常）也相似，每天 40 毫克非布司他（1.3%）、每天 80 毫克非布司他（1.2%）和别嘌醇组（0.9%）。还提出了一项来自已发表研究的安全性数据的荟萃分析。
